Published in Gastroenterol Clin North Am on January 05, 2012
Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study. PLoS One (2014) 1.55
Evolution and dynamics of pancreatic cancer progression. Oncogene (2013) 1.25
Early detection and prevention of pancreatic cancer: is it really possible today? World J Gastroenterol (2014) 0.95
Microbiota, oral microbiome, and pancreatic cancer. Cancer J (2014) 0.88
Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model. Radiology (2014) 0.88
Liver transplant patients have a risk of progression similar to that of sporadic patients with branch duct intraductal papillary mucinous neoplasms. Liver Transpl (2014) 0.83
Potential effects of Mina53 on tumor growth in human pancreatic cancer. Cell Biochem Biophys (2014) 0.79
Epidemiology of pancreatic cancer. World J Gastroenterol (2016) 0.78
Association between alcohol consumption and pancreatic cancer risk: a case-control study. PLoS One (2015) 0.77
Familial pancreatic cancer: the case for prophylactic pancreatectomy in lieu of serial screening and shared decision making. Case Rep Oncol Med (2014) 0.77
Clinical Management of Pancreatic Cancer. J Adv Pract Oncol (2015) 0.75
Hierarchical models for semi-competing risks data with application to quality of end-of-life care for pancreatic cancer. J Am Stat Assoc (2016) 0.75
Current Status and Future Directions for Screening Patients at High Risk for Pancreatic Cancer. Gastroenterol Hepatol (N Y) (2017) 0.75
Pathological and prognostic role of mdig in pancreatic cancer. Genes Cancer (2017) 0.75
International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology (2006) 8.83
Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst (1999) 8.15
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst (2002) 6.58
The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet (1995) 5.83
Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology (2000) 5.40
Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science (2000) 4.87
Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet (1998) 4.67
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63
Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet (1996) 4.36
Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst (1997) 4.23
Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol (2006) 4.22
Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med (1995) 4.10
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst (2002) 3.65
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res (1996) 3.60
BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst (2003) 3.37
Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res (2004) 3.31
The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol (1990) 3.20
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res (1997) 3.17
Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol (2004) 3.10
Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol (2004) 2.82
Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med (1999) 2.77
Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet (2005) 2.65
The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res (2004) 2.54
Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res (2003) 2.49
Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol (2011) 2.42
AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology (1999) 2.34
SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene (2003) 2.32
Risk of pancreatic cancer in families with Lynch syndrome. JAMA (2009) 2.32
DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res (2006) 2.29
Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res (2002) 2.23
Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors. Cancer Res (2001) 2.10
PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res (2007) 2.06
The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol (2009) 2.04
The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet (1999) 2.03
The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2007) 2.03
Gain-of-function mutations associated with hereditary pancreatitis enhance autoactivation of human cationic trypsinogen. Biochem Biophys Res Commun (2000) 1.99
PALB2 mutations in European familial pancreatic cancer families. Clin Genet (2010) 1.99
Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. Cancer Res (2001) 1.96
Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res (2010) 1.92
Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice. Cancer Biol Ther (2003) 1.88
Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet (1998) 1.88
Mutations of human cationic trypsinogen (PRSS1) and chronic pancreatitis. Hum Mutat (2006) 1.80
Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol (2000) 1.79
Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs. Cancer Biol Ther (2002) 1.79
Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med (2006) 1.73
Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome. Cancer Res (1998) 1.73
Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol (1997) 1.70
Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol (2011) 1.65
Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA (2001) 1.64
p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene (1993) 1.62
Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology (2003) 1.59
Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res (2000) 1.57
Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst (2010) 1.57
The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region. J Pathol (1998) 1.56
Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet (1997) 1.55
Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers. Gastroenterology (2006) 1.55
Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg (1992) 1.55
Familial pancreatic cancer. Cancer J (2001) 1.51
Role of tumour markers, cytogenetics. Ann Oncol (1999) 1.51
Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology (2010) 1.49
Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol (2007) 1.49
Tumor M2-pyruvate kinase as tumor marker in exocrine pancreatic cancer a meta-analysis. Pancreas (2007) 1.45
Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer (2007) 1.45
New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol (2005) 1.45
CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas (2007) 1.39
Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol (2002) 1.36
Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology (2002) 1.32
Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas (2007) 1.32
Hereditary pancreatic cancer. Gastroenterology (2010) 1.31
Familial pancreatic cancer: a review. Semin Oncol (1996) 1.30
CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol (2007) 1.30
Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am (2002) 1.30
MDCT in Pancreatic adenocarcinoma: prediction of vascular invasion and resectability using a multiphasic technique with curved planar reformations. AJR Am J Roentgenol (2004) 1.29
Risk factors for cancer in hereditary pancreatitis. International Hereditary Pancreatitis Study Group. Med Clin North Am (2000) 1.26
Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor. Am J Gastroenterol (2002) 1.24
Carcinoembryonic antigen (CEA) in the diagnosis of pancreatic cancer. Cancer (1973) 1.24
Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res (2003) 1.22
Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol (2010) 1.20
The role of epigenetic alterations in pancreatic cancer. J Hepatobiliary Pancreat Surg (2006) 1.20
Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology (1998) 1.18
PALB2 mutations in familial breast and pancreatic cancer. Fam Cancer (2011) 1.18
Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev (2010) 1.17
Evaluation of the 4q32-34 locus in European familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2006) 1.16
Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer (2003) 1.16
Pancreatic cancer and the FAMMM syndrome. Fam Cancer (2007) 1.13
Detection of small pancreatic tumors with multiphasic helical CT. AJR Am J Roentgenol (2004) 1.12
CEA in tumors of other than colorectal origin. Semin Surg Oncol (1991) 1.09
Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Oncology (2004) 1.06
Molecular genetics of familial cutaneous melanoma. J Clin Oncol (1998) 1.05
Palladin is overexpressed in the non-neoplastic stroma of infiltrating ductal adenocarcinomas of the pancreas, but is only rarely overexpressed in neoplastic cells. Cancer Biol Ther (2007) 1.05
Heredity and multiple primary malignant neoplasms: six cancer families. Am J Med Sci (1967) 1.04
Mutational activation of K-ras in nonneoplastic exocrine pancreatic lesions in relation to cigarette smoking status. Cancer (1999) 1.03
Gene conversion between functional trypsinogen genes PRSS1 and PRSS2 associated with chronic pancreatitis in a six-year-old girl. Hum Mutat (2005) 1.02
American gastroenterological association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology (1999) 1.00
Peutz-Jeghers syndrome and screening for pancreatic cancer. Br J Surg (2006) 1.00
Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility study. Gastrointest Endosc (2011) 1.00
K-ras mutations in duodenal aspirate without secretin stimulation for screening of pancreatic and biliary tract carcinoma. Cancer (1999) 0.99
Confocal laser endomicroscopy in Barrett's esophagus and endoscopically inapparent Barrett's neoplasia: a prospective, randomized, double-blind, controlled, crossover trial. Gastrointest Endosc (2009) 3.46
MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res (2013) 2.71
Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut (2012) 2.17
EUS-guided biliary drainage for patients with malignant biliary obstruction with an indwelling duodenal stent (with videos). Gastrointest Endosc (2012) 2.15
Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol (2012) 1.99
A comparative evaluation of EUS-guided biliary drainage and percutaneous drainage in patients with distal malignant biliary obstruction and failed ERCP. Dig Dis Sci (2014) 1.96
EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointest Endosc (2010) 1.91
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst (2007) 1.65
A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res (2009) 1.65
Histologic and imaging features of mural nodules in mucinous pancreatic cysts. Clin Gastroenterol Hepatol (2011) 1.61
Enteral stenting versus gastrojejunostomy for palliation of malignant gastric outlet obstruction. Surg Endosc (2013) 1.30
Should we do EUS/FNA on patients with pancreatic cysts? The incremental diagnostic yield of EUS over CT/MRI for prediction of cystic neoplasms. Pancreas (2013) 1.14
Comparative analysis of traditional and coiled fiducials implanted during EUS for pancreatic cancer patients receiving stereotactic body radiation therapy. Gastrointest Endosc (2012) 1.10
Endoscopic ultrasound-guided fine needle aspiration improves the pre-operative diagnostic yield of solid-pseudopapillary neoplasm of the pancreas: an international multicenter case series (with video). Surg Endosc (2014) 1.07
Tumor size and location correlate with behavior of pancreatic serous cystic neoplasms. Am J Gastroenterol (2011) 0.95
MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1. Clin Cancer Res (2013) 0.93
Novel technique of auto-tunneling during peroral endoscopic myotomy (with video). Gastrointest Endosc (2013) 0.91
Genome-wide somatic copy number alterations in low-grade PanINs and IPMNs from individuals with a family history of pancreatic cancer. Clin Cancer Res (2012) 0.89
Gastrointestinal tract epithelial changes associated with taxanes: marker of drug toxicity versus effect. Am J Surg Pathol (2008) 0.88
Should patients with a strong family history of pancreatic cancer be screened on a periodic basis for cancer of the pancreas? Pancreas (2009) 0.86
The adoption of ablation therapy for Barrett's esophagus: a cohort study of gastroenterologists. Am J Gastroenterol (2002) 0.85
Endoscopic stenting for benign upper gastrointestinal strictures and leaks. Surg Endosc (2013) 0.85
Acetic-acid chromoendoscopy for Barrett's esophagus: the "pros". Gastrointest Endosc (2006) 0.81
A novel submucosal gel permits simple and efficient gastric endoscopic submucosal dissection. Gastroenterology (2013) 0.80
Confocal laser endomicroscopy. Gastrointest Endosc Clin N Am (2009) 0.80
Endoscopic ultrasound (EUS)-guided fiducial placement allows localization of small neuroendocrine tumors during parenchymal-sparing pancreatic surgery. Surg Endosc (2013) 0.80
Dose-dependent depth of tissue injury with carbon dioxide cryotherapy in porcine GI tract. Gastrointest Endosc (2012) 0.79
Serum miR-1290 as a marker of pancreatic cancer--response. Clin Cancer Res (2013) 0.79
Chromoendoscopy for Barrett's esophagus in the twenty-first century: to stain or not to stain? Gastrointest Endosc (2006) 0.79
Red flag imaging techniques in Barrett's esophagus. Gastrointest Endosc Clin N Am (2013) 0.79
Surveillance in individuals at high risk of pancreatic cancer: too early to tell? Gut (2010) 0.76
Much ado about very little (lamina propria)? Gastrointest Endosc (2012) 0.76
Pancreatic Cysts - Part 2: Should We Be Less Cyst Centric? Pancreas (2017) 0.75
Management of high-grade dysplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol (2006) 0.75